Lunit Oncology Revenue
Software Development • • 21-50 Employees
Lunit Oncology revenue & valuation
| Annual revenue | $3,764,420 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Software Development industry and current estimated revenues | $12,100,000 |
| Total funding | No funding |
Key Contacts at Lunit Oncology
Sherry Kan
Global Vp, Dept Head Of Product Management And Marketing
Deboleena Sarkar
Sr.Director Business Development
Kyongjin Lee
Marketing Director
Timothy Ritty
Director Of Biopharma Business Development, Oncology
Seungeun Lee
Medical Director
Yoojoo Lim
Medical Director
Mia Lee
Director, Marketing
Company overview
| Headquarters | XX |
| Website | |
| Founded | 2013 |
| Employees | 21-50 |
Lunit Oncology Email Formats
Lunit Oncology uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@lunit.io), used 32.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@lunit.io | 32.1% |
{first name}.{last name} | john.doe@lunit.io | 21.4% |
{first name} | john@lunit.io | 17.9% |
{first initial} | j@lunit.io | 10.7% |
{last name} | doe@lunit.io | 7.1% |
About Lunit Oncology
Lunit develops state-of-the-art AI-powered medical image analysis software, led by a team of 300+ people, including 70+ researchers, 10+ MDs, and 6 oncologists/pathologists. Our highly skilled team consistently publishes in prestigious journals such as the Journal of Clinical Oncology, Clinical Cancer Research, JITC, NPJ, Precision Oncology, and more. Our AI-powered multimodal analysis unlocks advances in oncology research and clinical practice. Lunit SCOPE IO enables comprehensive tumor microenvironment assessment through quantitative immune phenotyping and beyond, facilitating faster and more accurate biomarker identification. Lunit SCOPE uIHC offers quantification and feature scoring IHC analysis across tissue types, for any suite of IHC markers. Lunit SCOPE GP predicts genotype modalities, offering insights into specific gene expression, mutations, and more, directly from H&E images. Lunit technology optimizes clinical trial processes, powering PD-L1 scoring for Guardant Health's Galaxy PD-L1 tissue testing. Lunit collaborates globally to advance oncology therapeutic biomarkers, driven by the company’s commitment to innovation and excellence.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Lunit Oncology has 34 employees across 7 departments.
Departments
Number of employees
Funding Data
Lunit Oncology has never raised funding before.
Canada
Spain
Poland
LithuaniaFrequently asked questions
4.8
40,000 users
